QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:TSHA

Taysha Gene Therapies (TSHA) Stock Forecast, Price & News

Notice: Trading of Taysha Gene Therapies halted at 09:51 AM EST due to "LULD pause".
$3.32
-0.12 (-3.49%)
(As of 05/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.69
$3.72
50-Day Range
$3.07
$6.77
52-Week Range
$2.69
$26.99
Volume
388,297 shs
Average Volume
253,177 shs
Market Capitalization
$134.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.23
30 days | 90 days | 365 days | Advanced Chart
Receive TSHA News and Ratings via Email

Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

Taysha Gene Therapies logo

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Headlines

Taysha Gene Therapies Misses Q4 EPS by 7c
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TSHA
Fax
N/A
Employees
38
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.48 per share

Profitability

Net Income
$-174.52 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
23,556,000
Market Cap
$134.37 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/31/2022
Today
5/16/2022
Next Earnings (Confirmed)
5/16/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.53 out of 5 stars

Medical Sector

118th out of 1,423 stocks

Biological Products, Except Diagnostic Industry

19th out of 209 stocks

Analyst Opinion: 4.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Taysha Gene Therapies (NASDAQ:TSHA) Frequently Asked Questions

Is Taysha Gene Therapies a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Taysha Gene Therapies stock.
View analyst ratings for Taysha Gene Therapies
or view top-rated stocks.

When is Taysha Gene Therapies' next earnings date?

Taysha Gene Therapies is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022.
View our earnings forecast for Taysha Gene Therapies
.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) issued its quarterly earnings data on Thursday, March, 31st. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by $0.11.
View Taysha Gene Therapies' earnings history
.

What price target have analysts set for TSHA?

14 equities research analysts have issued 1 year target prices for Taysha Gene Therapies' shares. Their forecasts range from $25.00 to $44.00. On average, they expect Taysha Gene Therapies' stock price to reach $33.00 in the next year. This suggests a possible upside of 894.0% from the stock's current price.
View analysts' price targets for Taysha Gene Therapies
or view top-rated stocks among Wall Street analysts.

Who are Taysha Gene Therapies' key executives?
Taysha Gene Therapies' management team includes the following people:
  • Mr. R. A. Session II, Founder, Pres, CEO & Director (Age 43, Pay $634.63k) (LinkedIn Profile)
  • Mr. Kamran Alam CPA, M.B.A., Chief Financial Officer (Age 44, Pay $756.38k) (LinkedIn Profile)
  • Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M, Chief Medical Officer and Head of R&D (Age 52, Pay $501.78k)
  • Dr. Claire Aldridge Ph.D., Sr. VP & Chief of Staff and Bus. Operations
  • Mr. Frederick Porter Ph.D., Chief Technical Officer
  • Mr. Jim Rouse, Chief Information Officer
  • Mr. Timothy J. Douros J.D., Chief Legal Officer & Corp. Sec.
  • Ms. Tracy M. Porter, Chief People Officer
  • Ms. Emily McGinnis M.P.H., Chief Patient Officer & Head of Gov. Affairs
  • Ms. Mishima Gerhart, Chief Regulatory Officer & Head of Quality
When did Taysha Gene Therapies IPO?

(TSHA) raised $125 million in an initial public offering (IPO) on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.

What is Taysha Gene Therapies' stock symbol?

Taysha Gene Therapies trades on the NASDAQ under the ticker symbol "TSHA."

Who are Taysha Gene Therapies' major shareholders?

Taysha Gene Therapies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.42%), Nantahala Capital Management LLC (3.30%), Vanguard Group Inc. (2.50%), TimesSquare Capital Management LLC (1.65%), State Street Corp (1.23%) and JPMorgan Chase & Co. (1.09%). Company insiders that own Taysha Gene Therapies stock include Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II and Sean P Nolan.
View institutional ownership trends for Taysha Gene Therapies
.

Which major investors are selling Taysha Gene Therapies stock?

TSHA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Nantahala Capital Management LLC, and Northern Trust Corp.
View insider buying and selling activity for Taysha Gene Therapies
or view top insider-selling stocks.

Which major investors are buying Taysha Gene Therapies stock?

TSHA stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, JPMorgan Chase & Co., Vanguard Group Inc., GSA Capital Partners LLP, Thompson Siegel & Walmsley LLC, State Street Corp, Nisa Investment Advisors LLC, and UBS Group AG. Company insiders that have bought Taysha Gene Therapies stock in the last two years include Paul B Manning, Phillip B Donenberg, RA Session II, and Sean P Nolan.
View insider buying and selling activity for Taysha Gene Therapies
or or view top insider-buying stocks.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taysha Gene Therapies' stock price today?

One share of TSHA stock can currently be purchased for approximately $3.32.

How much money does Taysha Gene Therapies make?

Taysha Gene Therapies has a market capitalization of $134.37 million. The company earns $-174.52 million in net income (profit) each year or ($4.630010) on an earnings per share basis.

How many employees does Taysha Gene Therapies have?

Taysha Gene Therapies employs 38 workers across the globe.

What is Taysha Gene Therapies' official website?

The official website for Taysha Gene Therapies is www.tayshagtx.com.

How can I contact Taysha Gene Therapies?

Taysha Gene Therapies' mailing address is 2280 Inwood Road, DALLAS TX, 75235. The company can be reached via phone at 214-612-0000 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.